Ty800

DB04989InvestigationalProtein Based Therapies

Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific... It is being developed by AVANT Immunotherapeutics, Inc.

Mechanism: Ty800 is a vaccine developed via the deletion of the phoP/phoQ virulence regulatory genes of Salmonella typhi Ty2. This enables the immune system to detect the applicable antibodies present on the natural virus without risking the patient.
Curator reviewed
Primary indication: For the production of immunity to Salmonella typhi, the cause of typhoid fever.Curator reviewed
Code names: Ty800

What you can answer from here — as of April 02, 2025

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Ty800, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account